You are here

Engineering of a Novel CDN Nanoparticle Platform

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI112132-01A1
Agency Tracking Number: R43AI112132
Amount: $245,943.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2011 E University Drive
RANCHO DOMINGUEZ, CA 90220-6411
United States
DUNS: 58878682
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 GARY FUJII
 (310) 635-5502
 gfujii@molecularexpress.com
Business Contact
 GARY FUJII
Phone: (310) 635-5502
Email: gfujii@molecularexpress.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): For many years, the use of protein and peptide antigens to induce specific immune responses has been an area of intense effort with the goal of developing improved vaccines. In principle, this approach is attractive because it has the potential to provide immunological specificity, tighter control of manufacturing processes, and elimination of most of the secondary sources of materials or contaminants associated with the production of the immunogen. However, proteins andpeptides are typically ineffective at stimulating host immune responses when used as soluble antigens. Co-administration with immunostimulatory adjuvant molecules (IAMs) can significantly improve the immune response against protein and peptide antigens, but differences in their physicochemical properties often makes their delivery together to the cells of the immune system inefficient. Since protein and peptide antigens generally require administration with a strong adjuvant to induce potent immune re

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government